6996.HK

Premier Integrated Platform in APAC to Develop Innovative Therapies for Oncology Antengene Corporation Limited Successfully Listed on Main Board of SEHK

星期五, 十一月 20, 2020 - 6:15am

The offer shares initially offered under the International Offering have also been over-subscribed by approximately 13.5 times.

Key Points: 
  • The offer shares initially offered under the International Offering have also been over-subscribed by approximately 13.5 times.
  • Antengene Corporation Limited is a clinical-stage APAC biopharmaceutical company focused on innovative oncology medicines.
  • At Antengene, we focus on developing drug candidates with novel targets or MoAs and first-in-class potential to address significant unmet medical needs.
  • The vision of Antengene is to "Treat Patients Beyond Borders" through research, development and commercialization of first-in-class/best-in-class therapeutics.